Notably, they detected genetic alterations in 72 promoters, including those associated with known driver genes in CLL, e.g., BIRC3, IKZF3 and TP53, as well as the PAX5 super enhancer region. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.